{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T20:05:55Z","timestamp":1770840355447,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"DOI":"10.1186\/s12880-026-02155-z","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T08:34:15Z","timestamp":1768638855000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Physiological distribution and dosimetry of Al18F-NOTA-Pentixafor in humans"],"prefix":"10.1186","volume":"26","author":[{"given":"Xinyang","family":"Li","sequence":"first","affiliation":[]},{"given":"Xiao","family":"Jiang","sequence":"additional","affiliation":[]},{"given":"Ying","family":"Kou","sequence":"additional","affiliation":[]},{"given":"Yu","family":"He","sequence":"additional","affiliation":[]},{"given":"Jingkai","family":"Yi","sequence":"additional","affiliation":[]},{"given":"Dan","family":"Wang","sequence":"additional","affiliation":[]},{"given":"Kailin","family":"Qi","sequence":"additional","affiliation":[]},{"given":"Yingchun","family":"Li","sequence":"additional","affiliation":[]},{"given":"Ping","family":"Wu","sequence":"additional","affiliation":[]},{"given":"Yutang","family":"Yao","sequence":"additional","affiliation":[]},{"given":"Hao","family":"Lu","sequence":"additional","affiliation":[]},{"given":"Shirong","family":"Chen","sequence":"additional","affiliation":[]},{"given":"Meng","family":"Zhao","sequence":"additional","affiliation":[]},{"given":"Zhen","family":"Cao","sequence":"additional","affiliation":[]},{"given":"Zhuzhong","family":"Cheng","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"key":"2155_CR1","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1182\/blood-2005-08-3182","volume":"107","author":"JA Burger","year":"2006","unstructured":"Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006;107:1761\u201367. https:\/\/doi.org\/10.1182\/blood-2005-08-3182.","journal-title":"Blood"},{"key":"2155_CR2","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1158\/1078-0432.CCR-09-2329","volume":"16","author":"BA Teicher","year":"2010","unstructured":"Teicher BA, Fricker SP. CXCL12 (SDF-1)\/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16:2927\u201331. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-2329.","journal-title":"Clin Cancer Res"},{"key":"2155_CR3","doi-asserted-by":"publisher","first-page":"591386","DOI":"10.3389\/fonc.2021.591386","volume":"11","author":"S Santagata","year":"2021","unstructured":"Santagata S, Ieran\u00f2 C, Trotta AM, Capiluongo A, Auletta F, Guardascione G, et al. CXCR4 and CXCR7 signaling pathways: a focus on the cross-talk between cancer cells and tumor microenvironment. Front Oncol. 2021;11:591386. https:\/\/doi.org\/10.3389\/fonc.2021.591386.","journal-title":"Front Oncol"},{"key":"2155_CR4","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2967\/jnumed.121.263693","volume":"63","author":"AK Buck","year":"2022","unstructured":"Buck AK, Haug A, Dreher N, Lambertini A, Higuchi T, Lapa C, et al. Imaging of C-X-C motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using 68Ga-Pentixafor PET. J Nucl Med. 2022;63:1687\u201392. https:\/\/doi.org\/10.2967\/jnumed.121.263693.","journal-title":"J Nucl Med"},{"key":"2155_CR5","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3389\/fonc.2019.00770","volume":"9","author":"RA Werner","year":"2019","unstructured":"Werner RA, Kircher S, Higuchi T, Kircher M, Schirbel A, Wester H-J, et al. CXCR4-directed imaging in solid tumors. Front Oncol. 2019;9:770. https:\/\/doi.org\/10.3389\/fonc.2019.00770.","journal-title":"Front Oncol"},{"key":"2155_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1053\/j.semnuclmed.2023.09.002","volume":"54","author":"L Lindenberg","year":"2024","unstructured":"Lindenberg L, Ahlman M, Lin F, Mena E, Choyke P. Advances in PET imaging of the CXCR4 receptor: [68Ga]Ga-PentixaFor. Semin Nucl Med. 2024;54:163\u201370. https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.09.002.","journal-title":"Semin Nucl Med"},{"key":"2155_CR7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.15252\/emmm.201404698","volume":"7","author":"K Philipp-Abbrederis","year":"2015","unstructured":"Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, L\u00fcckerath K, et al. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med. 2015;7:477\u201387. https:\/\/doi.org\/10.15252\/emmm.201404698.","journal-title":"EMBO Mol Med"},{"key":"2155_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.7150\/thno.16576","volume":"7","author":"C Lapa","year":"2017","unstructured":"Lapa C, Schreder M, Schirbel A, Samnick S, Kort\u00fcm KM, Herrmann K, et al. [68Ga]Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - comparison to [18F]FDG and laboratory values. Theranostics. 2017;7:205\u201312. https:\/\/doi.org\/10.7150\/thno.16576.","journal-title":"Theranostics"},{"key":"2155_CR9","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1007\/s00259-022-05849-y","volume":"49","author":"AK Buck","year":"2022","unstructured":"Buck AK, Serfling SE, Lindner T, H\u00e4nscheid H, Schirbel A, Hahner S, et al. CXCR4-targeted theranostics in oncology. Eur J Nucl Med Mol Imag. 2022;49:4133\u201344. https:\/\/doi.org\/10.1007\/s00259-022-05849-y.","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2155_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1161\/HYPERTENSIONAHA.117.09975","volume":"71","author":"B Heinze","year":"2018","unstructured":"Heinze B, Fuss CT, Mulatero P, Beuschlein F, Reincke M, Mustafa M, et al. Targeting CXCR4 (CXC chemokine receptor type 4) for molecular imaging of aldosterone-producing adenoma. Hypertension. 2018;71:317\u201325. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.09975.","journal-title":"Hypertension"},{"key":"2155_CR11","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/RLU.0000000000002131","volume":"43","author":"Y Luo","year":"2018","unstructured":"Luo Y, Pan Q, Feng J, Cao X, Li F. Chemokine receptor CXCR4-targeted PET\/CT with 68Ga-Pentixafor shows superiority to 18F-FDG in a patient with Waldenstr\u00f6m macroglobulinemia. Clin Nucl Med. 2018;43:548\u201350. https:\/\/doi.org\/10.1097\/RLU.0000000000002131.","journal-title":"Clin Nucl Med"},{"key":"2155_CR12","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1038\/s41375-021-01376-1","volume":"35","author":"R Lewis","year":"2021","unstructured":"Lewis R, Maurer HC, Singh N, Gonzalez-Menendez I, Wirth M, Schick M, et al. CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness. Leukemia. 2021;35:2895\u2013905. https:\/\/doi.org\/10.1038\/s41375-021-01376-1.","journal-title":"Leukemia"},{"key":"2155_CR13","doi-asserted-by":"publisher","first-page":"e70064","DOI":"10.1002\/hem3.70064","volume":"8","author":"D Friedman","year":"2024","unstructured":"Friedman D, Mehtani DP, Vidler JB, Patten PEM, Hoogeboom R. Proliferating CLL cells express high levels of CXCR4 and CD5. Hemasphere. 2024;8:e70064. https:\/\/doi.org\/10.1002\/hem3.70064.","journal-title":"Hemasphere"},{"key":"2155_CR14","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1182\/blood.2022017235","volume":"143","author":"SP Treon","year":"2024","unstructured":"Treon SP, Sarosiek S, Castillo JJ. How I use genomics and BTK inhibitors in the treatment of Waldenstr\u00f6m macroglobulinemia. Blood. 2024;143:1702\u201312. https:\/\/doi.org\/10.1182\/blood.2022017235.","journal-title":"Blood"},{"key":"2155_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41375-020-01102-3","volume":"35","author":"LM Kaiser","year":"2021","unstructured":"Kaiser LM, Hunter ZR, Treon SP, Buske C. CXCR4 in Waldenstr\u00f6m\u2019s macroglobulinema: chances and challenges. Leukemia. 2021;35:333\u201345. https:\/\/doi.org\/10.1038\/s41375-020-01102-3.","journal-title":"Leukemia"},{"key":"2155_CR16","doi-asserted-by":"publisher","unstructured":"Kosmala A, Duell J, Schneid S, Serfling SE, Higuchi T, Weich A, et al. Chemokine receptor-targeted PET\/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [18F]FDG. Eur J Nucl Med Mol Imag. 2024;51. https:\/\/doi.org\/10.1007\/s00259-023-06489-6.","DOI":"10.1007\/s00259-023-06489-6"},{"key":"2155_CR17","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.2967\/jnumed.123.266074","volume":"64","author":"J Duell","year":"2023","unstructured":"Duell J, Buck AK, Hartrampf PE, Schl\u00f6telburg W, Schneid S, Weich A, et al. Chemokine receptor PET\/CT provides relevant staging and management changes in marginal zone lymphoma. J Nucl Med. 2023;64:1889\u201394. https:\/\/doi.org\/10.2967\/jnumed.123.266074.","journal-title":"J Nucl Med"},{"key":"2155_CR18","doi-asserted-by":"publisher","unstructured":"Mayerhoefer ME, Raderer M, Lamm W, Pichler V, Pfaff S, Weber M, et al. CXCR4 PET imaging of mantle cell lymphoma using [68Ga]Pentixafor: comparison with [18F]FDG-PET. Theranostics. 2021;11. https:\/\/doi.org\/10.7150\/thno.48620.","DOI":"10.7150\/thno.48620"},{"key":"2155_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-07025-w","author":"MA Spahn","year":"2025","unstructured":"Spahn MA, Loy TV, Celen S, Koole M, Deroose CM, Cawthorne C, et al. Selective PET imaging of CXCR4 using the Al18F-labeled antagonist LY2510924. Eur J Nucl Med Mol Imag. 2025, 52. https:\/\/doi.org\/10.1007\/s00259-024-07025-w.","journal-title":"Eur J Nucl Med And Mol Imag"},{"key":"2155_CR20","doi-asserted-by":"publisher","unstructured":"Cheng K, Wang S, Liu T, Pei J, Wang S, Liu J, et al. PET imaging of CXCR4 expression using [18F]AlF-NOTA-QHY-04 for hematologic malignancy and solid tumors. Theranostics. 2024;14. https:\/\/doi.org\/10.7150\/thno.99025.","DOI":"10.7150\/thno.99025"},{"key":"2155_CR21","doi-asserted-by":"publisher","first-page":"5986","DOI":"10.7150\/thno.75847","volume":"12","author":"S Kraus","year":"2022","unstructured":"Kraus S, Klassen P, Kircher M, Dierks A, Habringer S, G\u00e4ble A, et al. Reduced splenic uptake on 68Ga-Pentixafor-PET\/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis. Theranostics. 2022;12:5986\u201394. https:\/\/doi.org\/10.7150\/thno.75847.","journal-title":"Theranostics"},{"key":"2155_CR22","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.3390\/cancers13235920","volume":"13","author":"M Schottelius","year":"2021","unstructured":"Schottelius M, Herrmann K, Lapa C. In vivo targeting of CXCR4-New horizons. Cancers (Basel). 2021;13:5920. https:\/\/doi.org\/10.3390\/cancers13235920.","journal-title":"Cancers (basel)"},{"key":"2155_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00259-021-05196-4","volume":"49","author":"SM Jacobs","year":"2022","unstructured":"Jacobs SM, Wesseling P, de Keizer B, Tolboom N, Ververs FFT, Krijger GC, et al. CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [68Ga]Ga-Pentixafor\/[177Lu]Lu-pentixather. Eur J Nucl Med Mol Imag. 2022;49:481\u201391. https:\/\/doi.org\/10.1007\/s00259-021-05196-4.","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2155_CR24","doi-asserted-by":"publisher","first-page":"1533295","DOI":"10.3389\/fendo.2025.1533295","volume":"16","author":"Y Peng","year":"2025","unstructured":"Peng Y, Chen F, Yao R, Lan J, Fu Y, Ye K, et al. The value of targeted CXCR4 18F-AlF-NOTA-pentixafor PET\/CT for subtyping primary aldosteronism. Front Endocrinol (Lausanne). 2025;16:1533295. https:\/\/doi.org\/10.3389\/fendo.2025.1533295.","journal-title":"Front Endocrinol (lausanne)"},{"key":"2155_CR25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41592-020-01008-z","volume":"18","author":"F Isensee","year":"2021","unstructured":"Isensee F, Jaeger PF, Kohl SAA, Petersen J, Maier-Hein KH. nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation. Nat Methods. 2021;18:203\u201311. https:\/\/doi.org\/10.1038\/s41592-020-01008-z.","journal-title":"Nat Methods"},{"key":"2155_CR26","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.2967\/jnumed.122.264225","volume":"64","author":"AL Kesner","year":"2023","unstructured":"Kesner AL, Carter LM, Ramos JCO, Lafontaine D, Olguin EA, Brown JL, et al. MIRD Pamphlet No. 28, Part, 1: MIRDcalc-A software tool for Medical internal radiation dosimetry. J Nucl Med. 2023;64:1117\u201324. https:\/\/doi.org\/10.2967\/jnumed.122.264225.","journal-title":"J Nucl Med"},{"key":"2155_CR27","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.2967\/jnumed.122.264230","volume":"64","author":"LM Carter","year":"2023","unstructured":"Carter LM, Ocampo Ramos JC, Olguin EA, Brown JL, Lafontaine D, Jokisch DW, et al. MIRD Pamphlet No. 28, Part, 2: comparative evaluation of MIRDcalc dosimetry software across a compendium of diagnostic radiopharmaceuticals. J Nucl Med. 2023;64:1295\u2013303. https:\/\/doi.org\/10.2967\/jnumed.122.264230.","journal-title":"J Nucl Med"},{"key":"2155_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12964-025-02099-x","volume":"23","author":"H-T Kim","year":"2025","unstructured":"Kim H-T, Jeong J-Y, Huh W-K. Regulation of CXCR4 function by S1P1 through heteromerization. Cell Commun Signal. 2025;23:111. https:\/\/doi.org\/10.1186\/s12964-025-02099-x.","journal-title":"Cell Commun Signal"},{"key":"2155_CR29","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2967\/jnumed.114.151647","volume":"56","author":"K Herrmann","year":"2015","unstructured":"Herrmann K, Lapa C, Wester H-J, Schottelius M, Schiepers C, Eberlein U, et al. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor. J Nucl Med. 2015;56:410\u201316. https:\/\/doi.org\/10.2967\/jnumed.114.151647.","journal-title":"J Nucl Med"},{"key":"2155_CR30","doi-asserted-by":"publisher","first-page":"7984","DOI":"10.7150\/thno.61423","volume":"11","author":"RA Werner","year":"2021","unstructured":"Werner RA, Hess A, Koenig T, Diekmann J, Derlin T, Melk A, et al. Molecular imaging of inflammation crosstalk along the cardio-renal axis following acute myocardial infarction. Theranostics. 2021;11:7984\u201394. https:\/\/doi.org\/10.7150\/thno.61423.","journal-title":"Theranostics"},{"key":"2155_CR31","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1093\/humrep\/deaa379","volume":"36","author":"JJ Reavey","year":"2021","unstructured":"Reavey JJ, Walker C, Nicol M, Murray AA, Critchley HOD, Kershaw LE, et al. Markers of human endometrial hypoxia can be detected in vivo and ex vivo during physiological menstruation. Hum Reprod. 2021;36:941\u201350. https:\/\/doi.org\/10.1093\/humrep\/deaa379.","journal-title":"Hum Reprod"},{"key":"2155_CR32","doi-asserted-by":"publisher","first-page":"e172216","DOI":"10.1172\/jci.insight.172216","volume":"8","author":"F Lyu","year":"2023","unstructured":"Lyu F, Burzynski C, Fang YY, Tal A, Chen AY, Kisa J, et al. Maternal CXCR4 deletion results in placental defects and pregnancy loss mediated by immune dysregulation. JCI Insight. 2023;8:e172216. https:\/\/doi.org\/10.1172\/jci.insight.172216.","journal-title":"JCI Insight"},{"key":"2155_CR33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13287-020-02071-1","volume":"12","author":"W Gao","year":"2021","unstructured":"Gao W, Yang X, Du J, Wang H, Zhong H, Jiang J, et al. Glucocorticoid guides mobilization of bone marrow stem\/progenitor cells via FPR and CXCR4 coupling. STEM Cell Res Ther. 2021;12:16. https:\/\/doi.org\/10.1186\/s13287-020-02071-1.","journal-title":"STEM Cell Res Ther"},{"key":"2155_CR34","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1097\/RLU.0000000000005426","volume":"50","author":"M Chavoshi","year":"2025","unstructured":"Chavoshi M, Mirshahvalad SA, Kohan A, Ortega C, Metser U, Farag A, et al. CXCR4-targeted PET imaging in hematologic malignancies: a systematic review and meta-analysis. Clin Nucl Med. 2025;50:e7\u201316. https:\/\/doi.org\/10.1097\/RLU.0000000000005426.","journal-title":"Clin Nucl Med"},{"key":"2155_CR35","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1097\/RLU.0000000000005073","volume":"49","author":"A Waheed","year":"2024","unstructured":"Waheed A, Singh B, Watts A, Kaur H, Singh H, Dhingra K, et al. 68 Ga-Pentixafor PET\/CT for in vivo imaging of CXCR4 receptors in glioma demonstrating a potential for response assessment to Radiochemotherapy: preliminary results. Clin Nucl Med. 2024;49:e141\u20138. https:\/\/doi.org\/10.1097\/RLU.0000000000005073.","journal-title":"Clin Nucl Med"},{"key":"2155_CR36","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.1039\/d3bm00798g","volume":"11","author":"JK Seon","year":"2023","unstructured":"Seon JK, Kuppa SS, Kang JY, Lee JS, Park SA, Yoon TR, et al. Peptide derived from stromal cell-derived factor 1\u03b4 enhances the in vitro expression of osteogenic proteins via bone marrow stromal cell differentiation and promotes bone formation in in vivo models. Biomater Sci. 2023;11:6587\u201399. https:\/\/doi.org\/10.1039\/d3bm00798g.","journal-title":"Biomater Sci"},{"key":"2155_CR37","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.7150\/ijbs.65802","volume":"18","author":"N Zhang","year":"2022","unstructured":"Zhang N, Ma Q, You Y, Xia X, Xie C, Huang Y, et al. CXCR4-dependent macrophage-to-fibroblast signaling contributes to cardiac diastolic dysfunction in heart failure with preserved ejection fraction. Int J Biol Sci. 2022;18:1271\u201387. https:\/\/doi.org\/10.7150\/ijbs.65802.","journal-title":"Int J Biol Sci"},{"key":"2155_CR38","doi-asserted-by":"publisher","first-page":"108733","DOI":"10.1016\/j.celrep.2021.108733","volume":"34","author":"Z Benet","year":"2021","unstructured":"Benet Z, Jing Z, Fooksman DR. Plasma cell dynamics in the bone marrow niche. Cell Rep. 2021;34:108733. https:\/\/doi.org\/10.1016\/j.celrep.2021.108733.","journal-title":"Cell Rep"},{"key":"2155_CR39","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s00259-022-05980-w","volume":"50","author":"P Brugarolas","year":"2023","unstructured":"Brugarolas P, Wilks MQ, Noel J, Kaiser J-A, Vesper DR, Ramos-Torres KM, et al. Human biodistribution and radiation dosimetry of the demyelination tracer [18F]3F4AP. Eur J Nucl Med Mol Imag. 2023;50:344\u201351. https:\/\/doi.org\/10.1007\/s00259-022-05980-w.","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2155_CR40","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.freeradbiomed.2022.02.024","volume":"182","author":"WA Alasmari","year":"2022","unstructured":"Alasmari WA, El-Shetry ES, Ibrahim D, ElSawy NA, Eldoumani H, Metwally AS, et al. Mesenchymal stem-cells\u2019 exosomes are renoprotective in postmenopausal chronic kidney injury via reducing inflammation and degeneration. Free Radic Biol Med. 2022;182:150\u201359. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2022.02.024.","journal-title":"Free Radic Biol Med"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-026-02155-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-026-02155-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-026-02155-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:03:43Z","timestamp":1770836623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12880-026-02155-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2155"],"URL":"https:\/\/doi.org\/10.1186\/s12880-026-02155-z","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Sichuan Cancer Hospital (approval number: SCCSMC-01\u2013202-87) and conducted in compliance with Chinese regulations. The study was registered in the Chinese Clinical Trial Registry (ChiCTR2400090595) on October 9, 2024. All participants provided written informed consent prior to enrollment. The research was conducted in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}